Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Ishin Presses Govt to Commit to OTC-Like Drug Reform by FY2026
November 13, 2025
- Health Minister Says Govt Mulling Backing for Wholesaler Support
November 13, 2025
- LDP Study Group Seeks Uniform 5% Drug Price Hike, Warns of US MFN Spillover
November 12, 2025
- Japan’s 1st Biosimilars for Eylea, Actemra Get NHI Listing in November
November 11, 2025
- MOF Pushes Stronger Use of CEA for Pricy Meds towards FY2026 Budget
November 11, 2025
- Growth Strategy Council Seeks Stronger Drug Discovery Infrastructure in Economic Plan
November 11, 2025
- LDP Kampo Caucus Chief Wary of Removing Insurance Coverage
November 10, 2025
- LDP Panel Backs Support for Drug Wholesalers in Economic Package
November 10, 2025
- Downstream Providers Decry Growing Negative Margins at Ryukaikon
November 10, 2025
- Category A Priority Drugs Kept in Separate-Handling Clause under Distribution Guidelines
November 10, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
- Keytruda Faces 5th Price Cut under Special Re-Pricing; MSD Warns of Ripple Effects
November 6, 2025
- Chuikyo OKs Listing of Novartis’ Pluvicto, Peak Sales Outlook at 42.1 Billion Yen
November 6, 2025
- MOF Floats New Patient Cost Scheme, Eyes Revival of Old Copay System
November 6, 2025
- Reblozyl to Face 8% Cut, Vyloy 4% in February: CEA Adjustment
November 6, 2025
- Servier’s Voranigo Skips November Listing; GSK, BMS Drugs Also Absent
November 6, 2025
- Tepid Exchanges at Chuikyo over Public-Private Working Group Report
November 6, 2025
- Takaichi Pledges Balanced Approach to Drug Pricing, Off-Year Revisions
November 6, 2025
- Japan Launches Growth Strategy HQ, Sets Drug Discovery as Priority Field
November 5, 2025
- MHLW Clarifies When Generic Drug Mergers Must Be Reviewed by Antitrust Regulator
November 5, 2025
ページ
The number of newly listed generic drugs in Japan has fallen sharply over the past decade, reflecting structural changes in…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…